Literature DB >> 6722808

Effects of estradiol and tamoxifen on human breast cancer cells in serum-free culture.

P D Darbre, S Curtis, R J King.   

Abstract

ZR-75-1 human mammary cancer cells can be grown in serum-free medium in an estradiol- and tamoxifen-sensitive manner. Growth occurs both in monolayer and suspension culture, although serum is necessary during the initial plating of the cells in monolayer culture. Optimal stimulation of proliferation by estradiol occurs at 10(-8) and 10(-9) M. Tamoxifen alone weakly stimulated growth in a dose-dependent manner up to 10(-7) M, but inhibition was observed at 10(-6) M. This inhibition was not seen if the cells were cultured in 10% dextran:charcoal-treated fetal calf serum. This difference is ascribed to tamoxifen binding components in the serum. In the absence of serum, tamoxifen (10(-6) M) abolished the proliferative effect of estradiol at all concentrations of estradiol below 10(-7) M. Higher concentrations of estradiol partially overcame the tamoxifen effect. Consistent antiestrogenic effects of tamoxifen required an estradiol:tamoxifen ratio of 1:1000.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722808

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

Review 2.  Serum-free culture of carcinoma cell lines.

Authors:  P Collodi; C Rawson; D Barnes
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

3.  Elevated plasma tamoxifen levels in a patient with liver obstruction.

Authors:  M W DeGregorio; V J Wiebe; A P Venook; W M Holleran
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  A new serum-free method of measuring growth factor activities for human breast cancer cells in culture.

Authors:  M Ogasawara; D A Sirbasku
Journal:  In Vitro Cell Dev Biol       Date:  1988-09

5.  Estrogen mitogenic action. ii. negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications.

Authors:  D A Sirbasku; J E Moreno-Cuevas
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

6.  P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda; R D Dansey
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Calcium antagonism by the antioestrogen tamoxifen.

Authors:  A Lipton; I D Morris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.

Authors:  B Nakata; K D Albright; R M Barton; S B Howell; G Los
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.

Authors:  J A Henry; S Nicholson; C Hennessy; T W Lennard; F E May; B R Westley
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.

Authors:  Marion T Weigel; Zara Ghazoui; Anita Dunbier; Sunil Pancholi; Mitch Dowsett; Lesley-Ann Martin
Journal:  Breast Cancer Res       Date:  2012-05-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.